A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

被引：13
|
作者：
Slomovitz, B. M.
Lu, K. H.
Johnston, T.
Munsell, M.
Ramondetta, L. M.
Broaddus, R. R.
Coleman, R. L.
Walker, C.
Gershenson, D. M.
Burke, T. W.
Wolf, J.
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5502
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Ma, Brigette B. Y.
    Lui, Vivian W. Y.
    Hui, Edwin P.
    Lau, Cecilia P. Y.
    Ho, Kakiu
    Ng, Margaret H. L.
    Cheng, S. H.
    Tsao, Sai-Wah
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 413 - 420
  • [42] Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy
    Wang, Huan
    Li, Dandan
    Li, Xiaomao
    Ou, Xueling
    Liu, Suiling
    Zhang, Yu
    Ding, Jie
    Xie, Bo
    ONCOLOGY LETTERS, 2016, 12 (06) : 5029 - 5035
  • [43] A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Lupo, Letizia
    Finazzi, Maria Chiara
    Tozzi, Lorenzo
    Biamonte, Flavia
    Masciulli, Arianna
    Susini, Maria Chiara
    Pancrazzi, Alessandro
    Finazzi, Guido
    Paratore, Simona
    Marchioli, Roberto
    Bosi, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    Barosi, Giovanni
    BLOOD, 2010, 116 (21) : 143 - 143
  • [44] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
    Whorf, R. C.
    Hainsworth, J. D.
    Spigel, D. R.
    Yardley, D. A.
    Burris, H. A., III
    Waterhouse, D. M.
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
    Eva Juengel
    Johanna Engler
    Iyad Natsheh
    Jon Jones
    Ausra Mickuckyte
    Lukasz Hudak
    Dietger Jonas
    Roman A Blaheta
    BMC Cancer, 9
  • [46] mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells
    Cai, Yuchen
    Xia, Qing
    Su, Quanguan
    Luo, Rongzhen
    Sun, Yueli
    Shi, Yanxia
    Jiang, Wenqi
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 31 (04) : 904 - 912
  • [47] Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Tripsas, Christina K.
    Ioakimidis, Leukothea
    Warren, Diane
    Patterson, Christopher
    Heffner, Leonard
    Eradat, Herbert
    Gregory, Stephanie A.
    Thomas, Sheeba
    Advani, Ranjana
    Baz, Rachid
    Badros, Ashraf Z.
    Matous, Jeffrey
    Anderson, Kenneth C.
    Ghobrial, Irene M.
    BLOOD, 2011, 118 (21) : 1273 - 1274
  • [48] A PROSPECTIVE MULTI-INSTITUTIONAL PHASE II STUDY OF EVEROLIMUS (RAD001), AN MTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA. A POETIC CONSORTIUM TRIAL
    Kieran, M.
    Yao, X.
    Macy, M.
    Geyer, R.
    Cohen, K.
    MacDonald, T.
    Allen, J.
    Boklan, J.
    Smith, A.
    Nazemi, K.
    Gore, L.
    Trippett, T.
    DiRenzo, J.
    Narendran, A.
    Perentesis, J.
    Prabhu, S.
    Pinches, N.
    Robison, N.
    Manley, P.
    Chi, S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 19 - 20
  • [49] Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Gertz, Morie
    LaPlant, Betsy
    Camoriano, John
    Hayman, Suzanne
    Lacy, Martha
    Chuma, Stacey
    Harris, Brianna
    Leduc, Renee
    Rourke, Meghan
    Ansell, Stephen M.
    DeAngelo, Daniel
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven P.
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1408 - 1414
  • [50] Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
    Juengel, Eva
    Engler, Johanna
    Natsheh, Iyad
    Jones, Jon
    Mickuckyte, Ausra
    Hudak, Lukasz
    Jonas, Dietger
    Blaheta, Roman A.
    BMC CANCER, 2009, 9
12345